Market Signal Briefing

Crypto prices today are stabilizing after a volatile weekend marked by a significant decline and shifting macro sentiment.

Summary

Bitcoin trades back above $110K as crypto market value gains 3%.
Easing U.S.-China tensions and ETF optimism support the rebound.
Coinbase sees Q4 driven by liquidity growth and stablecoin demand.

The global cryptocurrency market added 3% in the past 24 hours to reach $3.8 trillion, recovering from last weekend’s flash crash that caused over $20 billion in liquidations.

Bitcoin climbed 1.2% to trade above $110,000, while Ethereum gained 2% to $4,041 after dipping to near $3,700. BNB, XRP, and Solana each rose between 1% and 2%. Despite the rebound, sentiment remains cautious. The Crypto Fear & Greed Index is unchanged at 29, signaling “fear.”

According to CoinGlass data, liquidations surged to $440 million,up 209% from the previous day, as leveraged traders faced renewed volatility. Total open interest rose 3% to $152 billion, and the Altcoin Season Index sits at 39, reflecting a neutral trend.

Easing trade tensions spark market recovery
A key reason behind today’s market rebound is confirmation that senior Chinese officials will meet with U.S. representatives this week to resolve trade issues ahead of the APEC Summit in South Korea.

The meeting was confirmed by Treasury Secretary Scott Bessent and Chinese state media. It comes as both countries exchange trade threats, raising fears of another round of tariffs.

China has recently suggested it could restrict shipments of rare earth minerals to the U.S., a move that could disrupt key manufacturing sectors. The country also hinted it could retaliate against any new tariffs and said it no longer relies heavily on American chips.

If the upcoming talks produce progress, analysts believe it could ease global uncertainty and renew demand for risk assets like Bitcoin and Ethereum.

Short-term catalysts driving optimism
Several near-term developments could sustain the recovery. The Federal Reserve’s Oct. 28–29 FOMC meeting is expected to deliver a 25 bps rate cut, already 95% priced in by futures markets. Lower rates typically weaken the dollar and support risk assets such as Bitcoin.

Meanwhile, new spot and altcoin ETF filings, such as Solana and XRP proposals, whose approval dates are drawing near, are generating optimism. Analysts anticipate that approval will increase institutional capital and further strengthen the market.

Three major trends are influencing the year’s last quarter, according to a recent Coinbase Institutional report. The company highlights growing stablecoin adoption, increased global liquidity, and a more defined policy direction.

According to the report, stablecoin trading and issuance are at their highest levels this year, while the global money supply continues to expand.

Together, these developments suggest a steadier outlook for crypto markets as monetary conditions loosen and institutional participation grows.

Journalist

Posted: October 20, 2025

Key Takeaways
Is this the time to buy Pump.fun’s native token?
While the market might be turning around, PUMP is still not bullish in the short term.

What needs to change for PUMP to become bullish?
A rising Open Interest and a rally past the $0.005 supply zone would flip the outlook bullishly.

Pump.fun [PUMP] saw an 11.87% surge in daily trading volume, and was up 2.45% in 24 hours at the time of writing. The Open Interest moved higher by 2.05% over the same period – Only indicative of minor bullish sentiment.

The utility token of the memecoin launch platform pump.fun benefited from Bitcoin’s [BTC] price bounce past the $108k short-term resistance. The altcoin market has also been doing well, including the memecoins.

Dogecoin [DOGE] hiked by 3.5% in 24 hours, and the market could have a bullish start to the week. However, traders should be aware that the longer-term structure of PUMP is bearish. Unless the price beats a key resistance zone at $0.0052, a bullish short-term outlook would be laced with risk.

Decoding PUMP’s price action

Source: PUMP/USDT on TradingView

On the 1-day chart, PUMP seemed to have a bearish market structure. When it fell below the swing low at $0.0048 (orange), the market structure shifted bearishly. Moreover, the selling pressure during the structure shift was so high on Friday that a large imbalance (white box) was left behind.

At the time of writing, PUMP was treading water beneath the 78.6% Fibonacci retracement level. Bulls will want this level flipped to support quickly and trigger a rally beyond $0.0052. The CMF had a reading of +0.04, showing that buying pressure was not significantly bullish.

Additionally, the RSI on the daily chart was still below neutral 50 – A sign that downward momentum was prevalent.

Since the Friday crash, the Spot CVD has slowly been climbing, underlining spot demand behind PUMP. While the Open Interest rose too, it has been leashed and motionless over the last two days

A hike in Open Interest alongside a rally past $0.005 would be an encouraging sight for PUMP bulls. Until then, a bearish short-term outlook would be preferable.

Disclaimer: The information presented does not constitute financial, investment, trading, or other types of advice and is solely the writer’s opinion

Akashnath S is a Senior Journalist and Technical Analysis expert at AMBCrypto. He specializes in dissecting price action, identifying key market trends through advanced chart patterns, and forecasting both short-term and long-term asset trajectories.
His distinct analytical method is grounded in his academic training as a Chemical Engineer. This background provides him with a systematic, process-oriented approach to market data, enabling him to analyze the complex dynamics of financial markets with precision and objectivity.
Having actively covered the cryptocurrency space since the landmark 2017 market cycle, Akashnath possesses years of experience navigating both bull and bear markets. This seasoned perspective is critical to his insightful reporting on market volatility and evolution.
As an active market participant, Akashnath enhances his analysis with crucial, hands-on experience. This practical application of his technical skills ensures his insights are not merely theoretical, but are also relevant and actionable for an audience looking to understand and navigate trading opportunities. He is dedicated to educating readers on the nuances of technical analysis, empowering them with the knowledge to make more informed financial decisions.

TLDR:

Ethereum price trades at $4,058 after a 3.98% daily gain, with traders eyeing recovery beyond $5,000.
Open interest in Ethereum futures dropped 45% from its peak, reducing market speculation pressure.
Technical analysts see a bullish setup if ETH reclaims $4,100 and holds it in the short term.
The MVRV Momentum death cross reappears, warning of potential correction before any major breakout.

Ethereum is back in focus as traders weigh whether its next move leads to a breakout or another pullback. The asset is holding near the $4,000 mark after weeks of choppy action, and market sentiment seems split. 

Some traders see the recent reset in leverage as a healthy sign, while others warn of a possible short-term correction. The tension is clear: bulls want a reclaim of key levels to confirm strength. The next few days could define whether Ethereum breaks higher or slips further.

Traders Watch Critical Levels as Ethereum Holds $4,000
Crypto analyst Daan Crypto Trades said Ethereum’s current setup looks technically sound. He explained that the retest of the 0.382 Fibonacci retracement level and the Daily 200EMA remains “healthy.” 

$ETH Technically, this retest of the .382 Fibonacci retracement level and Daily 200EMA are perfectly fine and healthy.

I would want to see this back above those previous cycle highs at $4.1K to get the momentum back in favor of the bulls.

If it can do so and hold there, I'd be… pic.twitter.com/wbqUPP5krp

— Daan Crypto Trades (@DaanCrypto) October 19, 2025

For him, the key lies in reclaiming $4,100, the previous cycle high. Holding that level, he added, could bring back bullish momentum and open the door for a new all-time high by year’s end.

Market data from CoinGecko at press time shows Ethereum trading at $4,058.40 with a daily trading volume of about $34 billion. 

The token has gained nearly 4% in 24 hours but remains down 2% for the week. These figures reflect a cautious recovery phase after recent liquidations wiped out excess leverage across the crypto market.

Trader Ted noted that Ethereum’s open interest has dropped by nearly 45% from its previous high, while price has only fallen by about 20%. 

He said this reset in speculation is constructive for a cleaner market rebound. If buying resumes from current levels, he projected a move toward $5,500 to $6,000 without overheating.

Market sentiment remains cautiously optimistic. Traders see the reduction in leveraged positions as a sign of more stable footing. However, technical signals suggest Ethereum still needs to prove it can sustain upward momentum.

Death Cross Reappears as On-Chain Data Turns Mixed
On-chain analyst Ali warned that the MVRV Momentum indicator has flashed a death cross, a pattern that last appeared before a steep drop from $3,300 to $1,400. He said the signal has returned, raising questions about the strength of the current rally.

The reappearance of this signal has left traders divided. 

Some view it as a temporary shakeout before a larger move higher, while others believe it hints at another leg down before recovery. The contrast between reduced leverage and bearish on-chain signals captures the current state of uncertainty.

Still, Ethereum’s broader setup looks resilient compared to earlier corrections. 

The token’s price holding near $4,000 suggests steady demand from both spot buyers and long-term holders. If it pushes back above $4,100 and maintains that level, analysts believe a strong year-end rally could follow.

Hence, the next directional move may depend on whether ETH attracts fresh momentum from these levels or stalls below resistance.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Executives from crypto industry leaders, including Ripple, Coinbase, Chainlink, Galaxy, Kraken, Uniswap, and Circle, will attend a roundtable with pro-crypto Democrats this week. This comes amid delays in crypto ETFs’ approval due to the U.S. government shutdown, dragging the crypto market lower.

Ripple, Coinbase, Other Top Crypto Executives to Meet Democrats
Several executives from the crypto industry will attend a roundtable with pro-crypto Senate Democrats on Wednesday, according to Crypto In America host Eleanor Terrett’s post on October 20. Senator Kirsten Gillibrand to lead the roundtable.

Chief executive officers (CEO) attending the roundtable include Coinbase’s Brian Armstrong, Chainlink’s Sergey Nazarov, Galaxy’s Mike Novogratz, Kraken’s Dave Ripley, and Uniswap’s Hayden Adams.

Crypto policy leaders such as Solana Policy Institute president Kristin Smith, Circle CSO Dante Disparte, Ripple CLO Stuart Alderoty, Jito CLO Rebecca Rettig, and a16z crypto GC Miles Jennings are also participating.

This meeting comes as negotiations with Republicans stalled following fallout and industry backlash over a leaked Democratic proposal to regulate DeFi. Crypto industry leaders such as Brian Armstrong and Jake Chervinsky claimed that the proposal would ban crypto rather than promote innovation.

Crypto executives are expected to discuss market structure legislation, decentralized finance (DeFi) regulatory framework, and the path forward for crypto policies.

Delays in Crypto ETF Approvals
The roundtable is crucial for the crypto market as it comes at a time when crypto ETFs are facing delays. While the U.S. government shutdown entered its fourth week, the meeting comes as the U.S. SEC missed the final deadline for many crypto ETFs. These include ETF decisions on Litecoin, Solana, and Ripple’s native coin XRP.

The delay in approvals and prolonged government shutdown have impacted investor sentiment. The crypto market crash saw over $850 billion wiped out as the total crypto market cap fell to $3.5 trillion. Moreover, the Crypto Fear & Greed Index shifted from greed to extreme fear in just a week.

Meanwhile, issuers are updating their applications with the Generic Listing Standards. Recently, the SEC asked issuers to withdraw their 19b-4 filings and change language to comply with the new listing standards for crypto ETFs.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

Cantonese Cat argues that Dogecoin remains structurally primed for a late-cycle surge that would track the pattern of prior crypto bull markets, insisting that the coin’s decisive move has not yet arrived. In a 50-minute market analysis published on Oct. 19, the analyst ties Dogecoin’s setup to liquidity cycles and inter-market signals, but emphasizes that the DOGE read is simple: the market hasn’t seen the characteristic Dogecoin breakout that, in past cycles, has coincided with Bitcoin’s final acceleration.

“Whenever you have Bitcoin going up, Dogecoin also is forming a pretty decent base,” he said, noting that DOGE has participated only marginally while Bitcoin has ground higher. The trigger, in his view, is explicit. “Once you have Doge breaking into all-time high… that can happen in a hurry… once you have Doge breaking [its] all-time high, generally that’s when the acceleration phase of Bitcoin begins.” He frames that relationship as a recurring feature of cycle dynamics rather than an exception, arguing that the absence of a Dogecoin all-time-high breakout is one of several reasons he rejects the thesis that the broader crypto cycle has already ended.

Is The Dogecoin Bull Run Over?
Cantonese Cat links that call to the broader backdrop of risk appetite and liquidity, but he repeatedly narrows the lens to DOGE itself. He characterizes recent price action as a wear-you-out phase—punctuated by a sharp deleveraging “last week… with a big giant wick”—that has hardened bearish sentiment without invalidating the longer-term structure. “We haven’t had Doge breaking the all-time high yet… We have the deleveraging event, but we haven’t had [the] breakout into all-time high,” he said, adding that the coin’s base-building is consistent with how earlier cycles have unfolded before rapid upside.

Part of his conviction stems from how he reads Bitcoin dominance and the timing of altcoin rotations. He argues that dominance has run for “2022, 2023, 2024, almost the bulk of 2025,” looks “a little bit tired,” and has been moving sideways for roughly a year. In his framework, a turn lower in dominance would not necessarily mean Bitcoin weakness; rather, it would imply outperformance by altcoins.

Dogecoin vs Bitcoin price analysis | Source: X @cantonmeow
“If we end the cycle right here… this will be the very first time ever that we haven’t had any rotations from Bitcoin to altcoins and we haven’t had that parabolic phase—and this time would be different.” He is explicit that he does not buy the “this time is different” narrative, stating, “I just don’t really think that the cycle is different from [the] previous [one]… because things are still playing out.”

The Dogecoin-specific takeaway is that the market’s recent stress does not negate the historical sequencing he expects. He argues that the coin’s signature move typically arrives after prolonged compression, often in a condensed window.

“Last time [it] only happened within like a couple months and next thing you know it’s just like whoa what happened,” he recalled, cautioning that DOGE’s acceleration window can open quickly once resistance gives way. That pattern recognition underpins his pushback against entrenched pessimism: “A lot of people are just extremely bitter about Doge because this cycle has been wearing everybody out,” he said, but he views that sentiment as typical of pre-breakout conditions rather than evidence of structural failure.

Cantonese Cat repeatedly stresses that he is not giving financial advice and allows that his call could be wrong. Still, he returns to the same fulcrum: Dogecoin hasn’t delivered the hallmark event of a completed cycle.

Until it does—or definitively fails—he treats the coin as coiled rather than concluded. “The reality [is], I just don’t really think that the cycle is different… We haven’t had that [DOGE] breakout,” he said, summing up the risk-on bias that animates his view. In other words, for traders positioning around late-cycle outcomes, his message is that the “Dogecoin moment” remains ahead of the tape—and that the bears could be early.

DOGE Is Price Targets
Although the analyst does not cite fresh DOGE targets in the Oct. 19 video, he defers to levels from his earlier work, where he laid out several price-target frameworks for Dogecoin. In those prior notes, he argued that DOGE could be entering Wave 3 of an Elliott Wave structure after reclaiming the 0.618 Fibonacci retracement of the previous impulse ($0.20088).

From that framework, he highlighted upside projections around $0.48 (1.0 extension), $0.89 (1.272), $1.23 (1.414), and $1.96 (1.618). In variant commentary, he has also floated outcomes $2.00+ if a breakout accelerates, and in a more speculative scenario—likely from a separate video—he said, “I’m going to lay down the case as to why I think DOGE can hit $4 this cycle…”.

At press time, DOGE traded at $0.201.

DOGE holds above the multi-year trend line, 1-day chart | Source: DOGEUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

In brief
Bittensor and Zcash have risen by 10% as Bitcoin rebounds following weekend trading.
BNB has taken a backseat as traders book profits and rotate to high-beta altcoins with renewed momentum.
Experts remain optimistic but note that the continuation of a bullish outlook is contingent on cooling macro fears.
Bitcoin’s weekend rebound has set off a selective rally in altcoins, with Bittensor and Zcash leading gains as BNB, last week’s top performer, slipped from focus.

Bitcoin’s rebound from $105,000 to an intraday high of $110,000 came as macroeconomic and geopolitical conditions showed signs of improvement.

The weekend’s strength has set the stage for renewed momentum in altcoins.

"Bitcoin's rally has renewed market confidence," Shawn Young, chief analyst of MEXC Research, told Decrypt. "Traders are now rotating capital into high beta assets to seek short-term outperformance," signaling a comeback in speculative appetite.

Bittensor rose 12% over the past 24 hours, extending gains from last week’s 11.1% rise. Zcash also advanced 10.2%, trimming a seven-day loss of 11.4%, according to CoinGecko. 

BNB, by contrast, has lost steam, down 12.3% over the week despite a modest 4.1% daily uptick. The rotation reflects typical market cycles, where shifting narratives and profit-taking after brief rallies redirect capital toward altcoins showing fresh momentum, Young said.

Despite the rebound in altcoins, Bitcoin’s market dominance held steady near 60%, indicating investors remain hesitant to move significantly away from the leading cryptocurrency.

“Over the next few weeks, the focus will shift to whether Bitcoin can hold its key support levels, Shivam Thakral, CEO of BuyUcoin, told Decrypt. "If it does, we could see momentum return, especially around narratives like AI, restaking, and tokenized assets.”

Young, however, expects the trend toward selective strength to continue.

"Altcoins are now entering a phase where selective strength matters more than broad-based rallies," he said. "The next leg would most likely depend on capital inflows extending beyond major Layer-1s into DeFi and AI-linked projects."

Experts who previously spoke to Decrypt maintain a cautiously optimistic stance, suggesting that the macro and geopolitical outlook needs to cool before an explosive uptrend emerges.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Bitcoin price has bounced back above the $110,000 mark after dipping to last week’s low of $103,660. Some analysts now believe the bottom might be in, with a fresh leg higher potentially in play.

Summary

Bitcoin price has reclaimed $110k as macro pressures cooled over the weekend.
Some analysts believe BTC price has bottomed out and an upside rally may resume.
Bearish arguments project a deeper correction below $100k.

According to data from crypto.news, Bitcoin (BTC) is up 3.1% over the past 24 hours, reclaiming the $110k level after flipping $107k into support. As of Oct. 20 morning (Asia time), BTC was trading around $110,430. This upward move helped lift the broader crypto market, pushing the total market cap back above $3.8 trillion.

One likely reason for the bounce is that investors have started buying the dip after a sharp correction across the board, with many altcoins dropping more than 20% from their monthly highs.

The broader market sentiment also appears to be improving on hopes that the escalating U.S.–China trade tensions could cool down in the coming days. U.S. President Donald Trump is expected to meet Chinese President Xi Jinping at the Asia-Pacific Economic Cooperation (APEC) summit in South Korea later this month.

Ahead of that meeting, U.S. Treasury Secretary Scott Bessent and China’s Vice Premier He Lifeng are scheduled to hold talks in Malaysia, a move seen as a step toward de-escalation.

A breakthrough in negotiations would likely be seen as bullish for both crypto and traditional markets. Not only would it ease geopolitical tensions that triggered a wave of forced liquidations earlier this month, but it could also help tame inflationary pressures. That, in turn, could support the Federal Reserve’s pivot toward easing. 

Fed Chair Jerome Powell struck a dovish tone in his recent speech, hinting that the Fed’s balance sheet runoff, quantitative tightening, may be nearing its end, and that at least two more interest-rate cuts remain on the table.

Bitcoin bottom is over: analysts
After Bitcoin’s strong rebound back above $110k, several analysts are calling the bottom in. Popular trader CryptoPulse pointed out that $104,000 has held firm as the floor for this pullback, calling it “the clear bottom for this dip.” In their view, the next major move is likely a climb toward $150,000, a level they describe as the “final leg everyone’s been waiting for.”

Technical setups also appear to support this outlook. As seen in a chart shared by FriedrichBtc, Bitcoin’s daily RSI had slipped into oversold territory just before the bounce, often viewed as a signal that selling pressure is exhausted. Friedrich believes $135,000 is the next key level to watch, now that buyers have stepped in near support.

Bitcoin price has hit bottom | Source: X/FriedrichBtc
Both analysts emphasize that now may be the ideal time to position ahead of a breakout. 

“Don’t wait until it’s running — set up now while it’s still calm,” wrote CryptoPulse. 

The chart setups shared by both traders suggest a textbook trend reversal with higher lows beginning to form just above the $104k region. Based on their projections, BTC will gradually climb through the $120k and $130k ranges before eventually making a move toward $135k to $150k in the coming weeks, assuming macro conditions remain favorable.

However, not all analysts agree about the sustainability of Bitcoin’s latest bounce. Among that cohort is fellow trader and analyst Captain Faibik, who remained cautious, warning that while the short-term setup may look bullish, the bigger picture is still shaky. 

In his latest X post, he stressed that the broader uptrend could be running out of steam as BTC was still trading within a rising wedge pattern, a structure that historically breaks to the downside.

Bitcoin price has formed a bearish reversal pattern — Source: X/CryptoFaibik
Faibik acknowledges that bulls are still in control for now, especially with BTC holding above the weekly 50-day moving average.

“The Bitcoin bull run is over, and now late buyers are likely to get trapped,” the analyst wrote.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

US bitcoin ETFs saw $1.23 billion flow out last week, marking their second-largest weekly outflow since launch.

After a choppy stretch in the market, Solana price is testing key support levels as the market looks for signs of a broader recovery.

Summary

Solana currently trades at $192, holding support at $175 even as it remains stuck in a broader downtrend marked by lower highs and lows.
Institutional confidence continues to grow, with a Grayscale report highlighting Solana’s expanding ecosystem and ARK Invest reporting $223 million in Q3 network revenue, among the highest in the industry.
Corporate adoption is accelerating, as firms collectively hold more than 20 million SOL, signaling strong long-term interest that could help fuel a trend reversal.

Solana is trading around $192 at press time, up nearly 3% in the past 24 hours but still down about 1% for the week, per market data from crypto.news. The token’s price action has been choppy, holding key support but struggling to gain momentum.

Last week, SOL (SOL) dipped sharply but found strong support at $175, a level that has acted as a reliable floor since August. Each time the price approaches this mark, buyers step in, showing that there is real interest in defending the level.

Since the bounce, Solana price has pushed back above $190 and now hovers near resistance, needing a clear break of $192 to set up a renewed advance toward $200.​

Solana price chart | Source: TradingView
The daily chart, marked by continuous lower highs and lower lows, signals an emerging downtrend. Even as Solana manages short-term rallies, it remains confined within a descending channel, pointing to caution in the weeks ahead. Until it manages a convincing breakout above this pattern, further upside could be limited, keeping it vulnerable to renewed selling pressure.

Despite the technical weakness, strong institutional and corporate interest could soon provide the momentum Solana needs for a breakout.

Catalysts that may drive the next Solana price move
A steady drumbeat of positive news continues to build around Solana, offering plenty of fuel for a potential trend reversal. A recent Grayscale report paints Solana as a leader among crypto networks, thanks to its high volume, speed, and growing developer ecosystem.

The report calls Solana a “financial bazaar,” stressing its role in supporting thousands of applications and handling heavy user activity with very low fees.

ARK Invest adds more fuel with its Q3 update, showing the network’s revenue hit $223 million, one of the highest among all blockchains. This money comes from real on-chain usage, signaling strong demand for Solana’s services in NFTs, DeFi, and payments.

Big players like ARK have taken on large SOL positions, and other asset managers continue to add to their reserves. This ongoing accumulation is an important sign that institutional interest remains strong, even as prices have softened lately.​

Corporate treasury adoption also continues to pace, with digital asset companies and public firms collectively holding over 20 million SOL, as previously reported by crypto.news. Companies like Forward Industries and Solana Company are leading this charge, amassing millions of tokens and staking SOL to generate additional yield. 

Looking ahead, rising institutional demand, strong revenue growth, and expanding treasury holdings could give Solana price the push it needs to break its downtrend. ETF progress and upcoming network upgrades may also help if overall market sentiment improves, potentially setting up a recovery above the $200 level.

9h35 ▪
4
min read ▪ by
Luc Jose A.

Summarize this article with:

XRP is making an unexpected breakthrough in regulated markets. Driven by a record third quarter for the CME, derivatives linked to the asset are exploding, attracting a massive influx of institutional investors. Volumes soaring, open interest at its highest: the XRP futures market reaches unprecedented levels. This dynamic, far from a mere passing craze, marks a strategic turning point for cryptos outside the BTC/ETH duo. A new era opens, where alternative assets gain legitimacy in traditional financial circuits.

In Brief

XRP records a spectacular breakthrough in regulated markets, driven by a record quarter for the CME.
More than 476,000 XRP futures contracts have been traded since May 2025, totaling 23.7 billion dollars.
Open Interest reaches 1.4 billion dollars and the number of large institutional investors sets a record at 29.
CME plans to launch trading starting in 2026, aligning regulated markets with the native functioning of crypto.

XRP Joins the Big Leagues on the CME
Since their launch last May, XRP futures contracts have triggered unprecedented enthusiasm, especially from institutional investors.

The CME Group, in its Crypto Insights October report, reports that the XRP derivative product range, including Futures and Micro Futures, has quickly gained adoption, reaching record levels within a few months.

The institution notes : “the third quarter showed a strong rise in demand for regulated crypto exposures, with futures contracts on Solana (SOL) and XRP reaching historic highs”.

The published data is unequivocal and highlights the scale of the phenomenon :

476,000 XRP contracts have been traded since May ;
A total notional value of 23.7 billion dollars has been reached ;
Open Interest peaked at 1.4 billion dollars in September ;
The number of large open interest holders (LOIH) reached 29, an absolute record for XRP products on the CME.

This spectacular surge reflects a trend linked to the gradual shift of some institutional investors towards alternative assets to bitcoin and Ethereum, provided they are accessible through regulated products.

The XRP case is even more notable as it was long perceived as a legally uncertain asset. The fact that it now finds its place in institutional portfolios via regulated derivatives indicates a strategic repositioning of these actors in front of a market undergoing diversification.

The CME Capitalizes on the Enthusiasm for Regulated Assets
Beyond the specific performance of XRP contracts, it is the entire CME crypto derivatives market that reached a historic peak in the third quarter.

Indeed, the CME recorded more than 900 billion dollars in combined volume on crypto futures and options. The average daily Open Interest climbed to 31.3 billion dollars, and the total number of LOIH now stands at 1,014, marking an institutional participation never seen before. These figures reflect a structural shift in the engagement of professional investors in regulated crypto markets.

To support this momentum, the CME launched on October 13 the first options on XRP and Solana approved by the CFTC, the only ones currently authorized in the United States for these assets. The group also plans to go further, with the trading launch scheduled for early 2026, to align its hours with the uninterrupted nature of digital markets. “These are the only XRP and Solana options approved by the CFTC in the US, offering a trusted platform for efficient capital trading”, the official statement emphasizes.

This acceleration reveals several implications for the market. In the short term, it confirms the rise of a regulated ecosystem no longer limited to the two heavyweights bitcoin and Ethereum. In the medium term, the CME seems to position itself as a strategic bridge between traditional financial infrastructures and the crypto universe. By adopting a more flexible model, it adapts to the standards of Web3 while meeting the demands of Wall Street.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Luc Jose A.

Diplômé de Sciences Po Toulouse et titulaire d'une certification consultant blockchain délivrée par Alyra, j'ai rejoint l'aventure Cointribune en 2019.
Convaincu du potentiel de la blockchain pour transformer de nombreux secteurs de l'économie, j'ai pris l'engagement de sensibiliser et d'informer le grand public sur cet écosystème en constante évolution. Mon objectif est de permettre à chacun de mieux comprendre la blockchain et de saisir les opportunités qu'elle offre. Je m'efforce chaque jour de fournir une analyse objective de l'actualité, de décrypter les tendances du marché, de relayer les dernières innovations technologiques et de mettre en perspective les enjeux économiques et sociétaux de cette révolution en marche.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before December 15, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. MoonLake misled the market about its drug candidate, sonelokimab (SLK), which it claimed was superior to other monoclonal antibodies. The Company consistently touted its superiority while knowing it had no proven advantages over other treatments. The Company announced the results of a Phase 3 trial of SLK, disclosing what analysts labeled a "disastrous result," leading to its shares losing almost 90% of their value. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about MoonLake, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

October 20, 2025 02:00 ET

 | Source:

VAALCO Energy, Inc.

HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“Vaalco” or the “Company”) today announced the timing of its third quarter 2025 earnings release and conference call.

The Company will issue its third quarter 2025 earnings release on Monday, November 10, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Tuesday morning, November 11, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.)

Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the “Vaalco Energy Earnings Conference Call.” This call will also be webcast on VAALCO’s website at www.vaalco.com. An audio replay will be available on the Company’s website following the call.

About Vaalco

Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d’Ivoire, Equatorial Guinea, Nigeria and Canada.

For Further Information   Vaalco Energy, Inc. (General and Investor Enquiries)+00 1 713 543 3422Website:www.vaalco.com  Al Petrie Advisors (US Investor Relations)+00 1 713 543 3422Al Petrie / Chris Delange   Buchanan (UK Financial PR)+44 (0) 207 466 5000Ben Romney / Barry [email protected]  

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Quanex Building Products Corporation ("Quanex" or "the Company") (NYSE: NX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between December 12, 2024 and September 5, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 18, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Quanex "underinvested" in tooling and equipment maintenance for its Tyman Mexico facility. The Company's tooling and equipment had degraded to "catastrophic" levels due to its poor maintenance practices. The Company was likely to incur significant expenses to repair equipment, delaying the benefit of its Tyman integration. The Company was aware of these issues before they became serious. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Quanex, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

CALGARY, AB / ACCESS Newswire / October 20, 2025 / Tocvan Ventures Corp. ("Tocvan" or the "Company") (CSE:TOC)(OTCQB:TCVNF)(WKN:TV3/A2PE64), is pleased to announce the mobilization of equipment to both the North and South Blocks of its flagship Gran Pilar Gold-Silver Project in Sonora, Mexico. This marks a significant step forward in preparing the site for upcoming drilling, trenching activities, and ground preparation for the planned pilot mine operation.

, /PRNewswire/ -- HD Hyundai announced that Executive Vice Chairman Chung Kisun has been promoted to Chairman in its latest executive appointments.

Chung Kisun, HD Hyundai Chairman

Chairman Chung holds a bachelor's degree in Economics from Yonsei University and an MBA from Stanford University in the United States. He began his career in 2009 in the Finance Team of the Corporate Planning Division at HD Hyundai Heavy Industries. Since then, he has served as Head of Management Support at HD Hyundai, Head of Ship Sales at HD Hyundai Heavy Industries, and CEO of HD Hyundai Marine Solution. He currently serves as CEO of HD Hyundai, the holding company, as well as HD Korea Shipbuilding & Offshore Engineering, the intermediate holding company for the shipbuilding division. In this latest personnel announcement, Chairman Chung was also appointed Co-CEO of HD Hyundai XiteSolution, where he will lead efforts to overcome the recent downturn in the construction equipment business and establish new growth drivers.

Chairman Chung spearheaded the establishment of HD Hyundai Marine Solution in 2016, developing it into one of the group's core businesses with a market capitalization of KRW 11 trillion. In 2021, he led the acquisition of Doosan Infracore, nurturing the construction equipment business into another key growth pillar for the group. As Executive Vice Chairman, he directly oversaw major strategic issues across the HD Hyundai Group. More recently, he has focused on securing the company's future growth engines — including artificial intelligence (AI), digital innovation, and eco-friendly core technologies — while strengthening cooperation with the United States, which has renewed its commitment to revitalizing the shipbuilding industry, by engaging with key U.S. figures.

An HD Hyundai official stated, "This appointment reflects our determination to pioneer a new era under strong leadership amid an increasingly competitive and diversified global business environment," adding "By maintaining our leadership in the shipbuilding industry, HD Hyundai will contribute to the success of the Korea–U.S. Shipbuilding Cooperation Project, as well as to the growth of the Korean economy and the advancement of national interests."

SOURCE HD Hyundai

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fly-E Group, Inc. ("Fly-E" or "the Company") (NASDAQ: FLYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between July 15, 2025, and August 14, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Fly-E shared optimistic revenue goals with investors only for its actual performance to fall far short of its projections. The Company overstated its brand reputation, cost reductions, and ability to secure favorable pricing from suppliers. The Company failed to successfully grow its sales network. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fly-E, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

-

– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat population –

– Exelixis plans to complete its first new drug application submission for zanzalintinib in the U.S. in 2025 –

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met one of its dual primary endpoints, demonstrating a 20% reduction in the risk of death with the combination in the intention-to-treat (ITT) population at the final analysis (stratified hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.69-0.93; P=0.0045). At a median follow-up of 18.0 months, median overall survival (OS) in the ITT population was 10.9 months with zanzalintinib in combination with atezolizumab versus 9.4 months with regorafenib. Detailed findings from the study, including OS and progression-free survival (PFS) in the ITT population and in the subset of patients without liver metastases, are being presented today at the 2025 European Society for Medical Oncology (ESMO) Congress during the Proffered Paper Session 2: GI Tumours, Lower Digestive at 9:25 a.m. CEST and simultaneously published in The Lancet.

“While treating non-MSI-high metastatic colorectal cancer remains a challenge, the combination of zanzalintinib and atezolizumab has shown consistent benefits across key subgroups of patients,” said Anwaar Saeed, M.D., Section Chief of Gastrointestinal Oncology at the University of Pittsburgh, Director of the Gastrointestinal Disease Center at UPMC Hillman Cancer Center and a lead investigator of the trial. “STELLAR-303 is the first immunotherapy-based phase 3 trial that demonstrated improved overall survival with a differentiated kinase inhibitor compared to a standard of care in this patient population. The survival benefit was demonstrated early and was consistent throughout the trial, underscoring the combination’s potential for patients in need of a new and effective treatment option after disease progression.”

An OS benefit with the combination was consistently observed across pre-specified subgroups, including geographic region, RAS status, liver involvement and prior anti-VEGF therapy, as presented in Table 1 below. The 12- and 24-month landmark OS estimates were 46% (95% CI: 41-51) and 20% (95% CI: 15-26), respectively, for the combination of zanzalintinib and atezolizumab, and 38% (95% CI: 34-43) and 10% (95% CI: 6-16), respectively, for regorafenib.

TABLE 1

Median OS, months (95% CI)

HR (95% CI)

Zanzalintinib + Atezolizumab

Regorafenib

Geographic region

Asia

11.5 (9.2-13.7)

8.8 (7.8-10.4)

0.77 (0.59-1.00)

Rest of the world

10.9 (9.3-12.3)

9.8 (8.3-10.9)

0.82 (0.68-0.99)

RAS status

Wild type

12.0 (10.1-14.6)

10.4 (8.7-12.3)

0.79 (0.61-1.01)

Mutant

10.3 (9.0-11.9)

8.7 (8.1-9.8)

0.80 (0.66-0.98)

Active liver metastases

Presence

8.9 (8.0-9.9)

7.7 (6.5-8.5)

0.78 (0.65-0.94)

Absence

15.9 (13.5-17.6)

12.8 (10.9-15.5)

0.77 (0.59-1.01)

Prior anti-VEGF antibody treatment

Yes

10.6 (9.3-12.5)

8.8 (8.3-9.9)

0.80 (0.68-0.95)

No

11.5 (8.7-13.5)

11.1 (9.5-12.6)

0.80 (0.56-1.15)

OS = overall survival; CI = confidence interval; HR = hazard ratio; VEGF = vascular endothelial growth factor

Data pertaining to the other dual primary endpoint, OS in patients without liver metastases (non-liver metastases, NLM), were immature at the data cutoff. A prespecified interim analysis showed a trend in OS favoring the combination (15.9 months versus 12.8 months; stratified HR: 0.79; 95% CI: 0.61-1.03; P=0.0875) at a median follow-up of 16.8 months. The trial will proceed to the planned final analysis for this endpoint.

“These detailed results from STELLAR-303 provide further insight into the combination of zanzalintinib and atezolizumab as a potential new option to extend survival in patients with previously treated metastatic colorectal cancer,” said Dana T. Aftab, Ph.D., Executive Vice President, Research and Development, Exelixis. “Before the end of this year, we intend to complete the submission of our first new drug application for zanzalintinib as we work toward bringing this combination regimen to a patient community seeking a new and chemotherapy-free option. These data, along with our robust clinical trial program, underscore the progress we are making toward our goal of increasing the scope and scale of the solid tumor types zanzalintinib may help address.”

A trend for improvement in PFS with the combination was also observed in the ITT population (stratified HR: 0.68 [95% CI: 0.59–0.79]; median, 3.7 [95% CI: 3.5–3.8] months versus 2.0 [95% CI: 1.9–2.6] months), though statistical superiority cannot be claimed at this time due to the prespecified hierarchical testing strategy. The trend for PFS improvement with zanzalintinib in combination with atezolizumab versus regorafenib was consistent across subgroups.

The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. Grade 3/4 treatment-related adverse events (AEs) occurred in 59% of patients receiving zanzalintinib in combination with atezolizumab and 37% of patients receiving regorafenib. AEs leading to discontinuation of all study treatment occurred in 18% versus 15% of patients, respectively. The most common grade 3/4 treatment-related AEs were hypertension (15% versus 9%, respectively), fatigue (6% versus 2%), diarrhea (6% versus 2%) and proteinuria (6% versus 2%). Deaths considered related to treatment by investigators were two for zanzalintinib, two for atezolizumab, one for the combination and one for regorafenib.

About STELLAR-303

STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized patients 1:1 to either zanzalintinib in combination with atezolizumab (n=451) or regorafenib (n=450). The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. Secondary endpoints include PFS, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at ClinicalTrials.gov.

About Zanzalintinib

Zanzalintinib is a novel oral kinase inhibitor that inhibits the activity of the TAM kinases (TYRO3, AXL, MER), MET and VEGF receptors. These kinases play important roles in oncogenic processes including tumor cell proliferation, metastasis, angiogenesis, drug resistance and evasion of antitumor immunity. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company’s flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer and neuroendocrine tumors.

Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

About CRC

CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S.1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025.1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent.2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%.2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy.3

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of detailed results from the STELLAR-303 pivotal trial at ESMO 2025; the therapeutic potential of zanzalintinib in combination with atezolizumab to become a new and effective treatment option to extend survival for patients with previously treated metastatic CRC; Exelixis’ plans to complete a new drug application submission for zanzalintinib in the U.S. in 2025; Exelixis’ progress in clinical trials towards the goal of increasing the scope and scale of solid tumor types zanzalintinib may address; and Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis’ continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis’ ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption “Risk Factors” in Exelixis’ most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis’ future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis.

TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group.

More News From Exelixis, Inc.

Back to Newsroom

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, Germany Paris, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212 isotope, underscore the first-in-class potential of this investigational medicine for the treatment of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Detailed results from the phase 2 study, the first to evaluate a TAT across both radioligand therapy (RLT)-naïve and RLT-exposed patients affected by GEP-NETs, were presented in two oral presentations at the 2025 European Society for Medical Oncology (ESMO) Congress, Berlin, Germany.

“Lead-212-based Targeted Alpha Therapy (TAT) could have a transformative impact across a broad range of solid tumors. With AlphaMedix’s consistent and clinically meaningful responses across both RLT-naïve and RLT-exposed gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients, the positive results underscore its potential in this rare and difficult-to-treat cancer,” said Volker Wagner, MD, PhD, Chief Medical Officer at Orano Med. “These data strongly encourage us to further advance the clinical development of AlphaMedix, and jointly with our partner, Sanofi, make this innovative TAT available to patients in need.”

ALPHAMEDIX-02 phase 2 study
ALPHAMEDIX-02 is a phase 2, open-label, multicenter study evaluating the efficacy and safety of AlphaMedix in patients with unresectable or metastatic SSTR+ GEP-NETs. The study included two cohorts evaluating RLT-naïve and RLT-exposed patients. The primary efficacy endpoint across both cohorts was the overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS).

The study's efficacy endpoints are based on local investigator assessment, per protocol. In addition, a blinded independent central review (BICR) was conducted subsequently. The key efficacy endpoints were met within both the investigator-assessed and BICR results.

The following results were presented:

RLT-Naïve
(n=35)
  Investigator assessment Independent assessment (BICR) *DOR is determined only for participants who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST 1.1
**Defined as the percentage of patients achieving CR or PR or SD per RECIST 1.1
***OS assessment is independent of RECIST 1.1 criteria, so BICR is n/a ORR 60.0%
(95% CI: 42.1-76.1) 57.1%
(95% CI: 39.4-73.7) Duration of Response (DoR) per Kaplan-Meier (KM) estimate (95% CI)* 71.9% for ≥ 24 months
(95% CI: 44.6-87.4) 81.7% for ≥ 24 months
(95% CI: 53.1-93.8) Complete Response (CR) - 2.9% Partial Response (PR) 60.0% 54.3% Stable Disease (SD) 34.3% 28.6% Disease control rate (DCR)** 94.3%
(95% CI: 80.8-99.3) 85.7%
(95% CI: 69.7-95.2) PFS 36-month PFS rate of 72.3%
(95% CI: 53.3-84.5) 36-month PFS rate of 63.3%
(95% CI: 40.3-79.4) OS 36-month OS rate of 88.2%
(95% CI: 71.5-95.4) Not applicable*** RLT-Exposed
(n=26)
  Investigator assessment Independent assessment (BICR) *DOR is determined only for participants who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST 1.1
**Defined as the percentage of patients achieving CR or PR or SD per RECIST 1.1
***OS assessment is independent of RECIST 1.1 criteria, so BICR is n/a ORR 34.6%
(95% CI: 17.2-55.7) 19.2%
(95% CI: 6.6-39.4) Duration of Response (DoR) per Kaplan-Meier (KM) estimate (95% CI)* 100% for ≥ 18 months
(95% CI: 100-100) 100% for ≥ 18 months
(95% CI: 100-100) Partial Response (PR) 34.6% 19.2% Stable Disease (SD) 61.5% 80.8% Disease control rate (DCR)** 96.2%
(95% CI: 80.4-99.9) 100%
(95% CI: 86.8-100) PFS 18-month PFS rate of 82.6%
(95% CI: 59.0-93.3) 18-month PFS rate of 88%
(95% CI: 67.3-96.0) OS 18-month OS rate of 85.1%
(95% CI: 58.5-95.2) Not applicable*** AlphaMedix™ had a similar safety profile across both cohorts. Within the RLT-naïve cohort, 85.7% of patients received all four doses of AlphaMedix, and 84.6% of patients within the RLT-exposed cohort. All GEP-NET patients experienced at least one treatment-emergent adverse event (TEAE). Grade ≥3 TEAEs occurred in 42.3% of RLT-exposed patients and 54.3% of RLT-naïve patients. The most common Grade ≥3 TEAEs in both groups was lymphocyte count decrease (25.7% of RLT-naïve patients and 15.4% of RLT-exposed patients).

“The future of oncology research will be driven by cutting-edge science and next-generation modalities, such as radioligand therapies. AlphaMedix, a promising targeted alpha therapy, embodies the type of solution Sanofi is working to advance,” said Christopher Corsico, MD, Global Head of Development at Sanofi. “We are excited to share these robust scientific findings at ESMO as the data could represent a significant advancement in how we treat gastroenteropancreatic neuroendocrine tumors. As we engage with health authorities and advance the clinical program, we remain focused on bringing this innovative modality to patients who need new treatment options”

Advancing AlphaMedix in GEP-NETs
RLTs, which work by delivering radiation directly to tumor cells, represent an emerging area of oncology research. While current approved beta-emitting RLTs have improved outcomes in patients with GEP-NETs, there remains a critical gap in care, including in those who have progressed following previous RLT.

TAT represents an innovative modality in RLT, harnessing high-energy, short-range alpha emissions to precisely target cancer cells while reducing potential exposure to surrounding tissue.

"The results observed in the ALPHAMEDIX-02 trial clearly demonstrate exceptional levels of efficacy for a Targeted Alpha Therapy (TAT), based on current available therapies, in both radioligand therapy (RLT)-naïve and RLT-exposed populations and could potentially set new expectations when treating gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with RLTs” said Ebrahim Delpassand, MD, Founder and Chairman, CEO of RadioMedix. “For too long, this patient population has experienced inadequate disease control with current approved therapies. This important work provides hope for a new treatment for GEP-NET patients, their caregivers, and their healthcare providers.”

In February 2024, AlphaMedix™ was designated as a breakthrough therapy by the US Food and Drug Administration in RLT-naïve patients with unresectable or metastatic GEP-NETs, recognizing the potential clinical benefits of lead-212–based TATs. The ALPHAMEDIX-02 results will form the basis for further discussions with health authorities.

An international phase 3 study to further evaluate AlphaMedix in GEP-NETs is actively being planned. AlphaMedix is an investigational medicine and has not been approved by any regulatory authority.

In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize AlphaMedix.

About the ALPHAMEDIX-02 study
ALPHAMEDIX-02 is a phase 2, open-label, multicenter study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE) in patients with histologically confirmed unresectable or metastatic GEP-NETs, positive somatostatin analogue imaging and at least one site of measurable disease. The study included two cohorts evaluating RLT-naïve (n=35) and RLT-exposed (n=26) GEP-NET patients. RLT-exposed patients had progressive disease after receiving up to four doses of 177Lu-DOTATATE and received their last dose at least six months prior to Day 1. In both cohorts, AlphaMedix was administered at 67.6 μCi/kg every eight weeks for up to four cycles (6 mCi maximum per cycle). The primary efficacy endpoint across both cohorts was ORR per RECIST 1.1. Secondary endpoints included PFS and OS.

About NETs
NETs are a heterogeneous group of cancers that originate from neuroendocrine cells. These cancers occur mostly in the gastrointestinal tract and pancreas but can also occur in other tissues including the thymus, lung, and other uncommon sites such as the ovaries, heart, and prostate. Most NETs strongly express somatostatin receptors. Despite the global prevalence of NETs increasing each year, it is considered a rare cancer that is estimated to affect approximately 35/100,000 individuals worldwide. In the United States, around 12,000 patients annually are expected to be diagnosed with neuroendocrine tumors, with an average five-year survival rate of 60% at a metastatic stage.

About Orano Med
Orano Med is a subsidiary of the Orano Group. Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha Therapy (TAT). Leveraging its unique and secured access to 212Pb, the company is developing several 212Pb-based radioligand therapies combined with various targeting agents. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe.

About RadioMedix
RadioMedix, Inc., a clinical-stage biotechnology company and former sponsor of the AlphaMedix trial, is based in Houston and Humble, Texas. The company is focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. RadioMedix is developing radiopharmaceuticals for PET imaging and therapy (alpha- and beta-labeled agents). The company established contract service facilities for academic and industrial partners. including a cGMP and analytical suite for Phase I-II-III clinical trials and commercial launch. To learn more, visit www.radiomedix.com and LinkedIn.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]  
Léo Le Bourhis | +33 6 75 06 43 81 | [email protected]  
Victor Rouault | +33 6 70 93 71 40 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]
Léa Ubaldi | +33 6 30 19 66 46 | [email protected]

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | [email protected]  
Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]
Felix Lauscher | +1 908 612 7239 | [email protected]  
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | +33 7 85 93 30 17 | [email protected]
Tarik Elgoutni | +1 617 710 3587 | [email protected]  
Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]

Orano Med
Regina Jehle | +33 6 74 56 11 31 | [email protected]
Orano Press Office | +33 (0)1 34 96 12 15| [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group with the exception of Orano Med and AlphaMedix™.

Press_Release

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, Germany Paris, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212 isotope, underscore the first-in-class potential of this investigational medicine for the treatment of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Detailed results from the phase 2 study, the first to evaluate a TAT across both radioligand therapy (RLT)-naïve and RLT-exposed patients affected by GEP-NETs, were presented in two oral presentations at the 2025 European Society for Medical Oncology (ESMO) Congress, Berlin, Germany.

“Lead-212-based Targeted Alpha Therapy (TAT) could have a transformative impact across a broad range of solid tumors. With AlphaMedix’s consistent and clinically meaningful responses across both RLT-naïve and RLT-exposed gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients, the positive results underscore its potential in this rare and difficult-to-treat cancer,” said Volker Wagner, MD, PhD, Chief Medical Officer at Orano Med. “These data strongly encourage us to further advance the clinical development of AlphaMedix, and jointly with our partner, Sanofi, make this innovative TAT available to patients in need.”

ALPHAMEDIX-02 phase 2 study
ALPHAMEDIX-02 is a phase 2, open-label, multicenter study evaluating the efficacy and safety of AlphaMedix in patients with unresectable or metastatic SSTR+ GEP-NETs. The study included two cohorts evaluating RLT-naïve and RLT-exposed patients. The primary efficacy endpoint across both cohorts was the overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS).

The study's efficacy endpoints are based on local investigator assessment, per protocol. In addition, a blinded independent central review (BICR) was conducted subsequently. The key efficacy endpoints were met within both the investigator-assessed and BICR results.

The following results were presented:

RLT-Naïve
(n=35)   Investigator assessment Independent assessment (BICR) *DOR is determined only for participants who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST 1.1
**Defined as the percentage of patients achieving CR or PR or SD per RECIST 1.1
***OS assessment is independent of RECIST 1.1 criteria, so BICR is n/a ORR 60.0%
(95% CI: 42.1-76.1) 57.1%
(95% CI: 39.4-73.7) Duration of Response (DoR) per Kaplan-Meier (KM) estimate (95% CI)* 71.9% for ≥ 24 months
(95% CI: 44.6-87.4) 81.7% for ≥ 24 months
(95% CI: 53.1-93.8) Complete Response (CR) - 2.9% Partial Response (PR) 60.0% 54.3% Stable Disease (SD) 34.3% 28.6% Disease control rate (DCR)** 94.3%
(95% CI: 80.8-99.3) 85.7%
(95% CI: 69.7-95.2) PFS 36-month PFS rate of 72.3%
(95% CI: 53.3-84.5) 36-month PFS rate of 63.3%
(95% CI: 40.3-79.4) OS 36-month OS rate of 88.2%
(95% CI: 71.5-95.4) Not applicable*** RLT-Exposed
(n=26)   Investigator assessment Independent assessment (BICR) *DOR is determined only for participants who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST 1.1
**Defined as the percentage of patients achieving CR or PR or SD per RECIST 1.1
***OS assessment is independent of RECIST 1.1 criteria, so BICR is n/a ORR 34.6%
(95% CI: 17.2-55.7) 19.2%
(95% CI: 6.6-39.4) Duration of Response (DoR) per Kaplan-Meier (KM) estimate (95% CI)* 100% for ≥ 18 months
(95% CI: 100-100) 100% for ≥ 18 months
(95% CI: 100-100) Partial Response (PR) 34.6% 19.2% Stable Disease (SD) 61.5% 80.8% Disease control rate (DCR)** 96.2%
(95% CI: 80.4-99.9) 100%
(95% CI: 86.8-100) PFS 18-month PFS rate of 82.6%
(95% CI: 59.0-93.3) 18-month PFS rate of 88%
(95% CI: 67.3-96.0) OS 18-month OS rate of 85.1%
(95% CI: 58.5-95.2) Not applicable*** AlphaMedix™ had a similar safety profile across both cohorts. Within the RLT-naïve cohort, 85.7% of patients received all four doses of AlphaMedix, and 84.6% of patients within the RLT-exposed cohort. All GEP-NET patients experienced at least one treatment-emergent adverse event (TEAE). Grade ≥3 TEAEs occurred in 42.3% of RLT-exposed patients and 54.3% of RLT-naïve patients. The most common Grade ≥3 TEAEs in both groups was lymphocyte count decrease (25.7% of RLT-naïve patients and 15.4% of RLT-exposed patients).

“The future of oncology research will be driven by cutting-edge science and next-generation modalities, such as radioligand therapies. AlphaMedix, a promising targeted alpha therapy, embodies the type of solution Sanofi is working to advance,” said Christopher Corsico, MD, Global Head of Development at Sanofi. “We are excited to share these robust scientific findings at ESMO as the data could represent a significant advancement in how we treat gastroenteropancreatic neuroendocrine tumors. As we engage with health authorities and advance the clinical program, we remain focused on bringing this innovative modality to patients who need new treatment options”

Advancing AlphaMedix in GEP-NETs
RLTs, which work by delivering radiation directly to tumor cells, represent an emerging area of oncology research. While current approved beta-emitting RLTs have improved outcomes in patients with GEP-NETs, there remains a critical gap in care, including in those who have progressed following previous RLT.

TAT represents an innovative modality in RLT, harnessing high-energy, short-range alpha emissions to precisely target cancer cells while reducing potential exposure to surrounding tissue.

"The results observed in the ALPHAMEDIX-02 trial clearly demonstrate exceptional levels of efficacy for a Targeted Alpha Therapy (TAT), based on current available therapies, in both radioligand therapy (RLT)-naïve and RLT-exposed populations and could potentially set new expectations when treating gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with RLTs” said Ebrahim Delpassand, MD, Founder and Chairman, CEO of RadioMedix. “For too long, this patient population has experienced inadequate disease control with current approved therapies. This important work provides hope for a new treatment for GEP-NET patients, their caregivers, and their healthcare providers.”

In February 2024, AlphaMedix™ was designated as a breakthrough therapy by the US Food and Drug Administration in RLT-naïve patients with unresectable or metastatic GEP-NETs, recognizing the potential clinical benefits of lead-212–based TATs. The ALPHAMEDIX-02 results will form the basis for further discussions with health authorities.

An international phase 3 study to further evaluate AlphaMedix in GEP-NETs is actively being planned. AlphaMedix is an investigational medicine and has not been approved by any regulatory authority.

In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize AlphaMedix.

About the ALPHAMEDIX-02 study
ALPHAMEDIX-02 is a phase 2, open-label, multicenter study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE) in patients with histologically confirmed unresectable or metastatic GEP-NETs, positive somatostatin analogue imaging and at least one site of measurable disease. The study included two cohorts evaluating RLT-naïve (n=35) and RLT-exposed (n=26) GEP-NET patients. RLT-exposed patients had progressive disease after receiving up to four doses of 177Lu-DOTATATE and received their last dose at least six months prior to Day 1. In both cohorts, AlphaMedix was administered at 67.6 μCi/kg every eight weeks for up to four cycles (6 mCi maximum per cycle). The primary efficacy endpoint across both cohorts was ORR per RECIST 1.1. Secondary endpoints included PFS and OS.

About NETs
NETs are a heterogeneous group of cancers that originate from neuroendocrine cells. These cancers occur mostly in the gastrointestinal tract and pancreas but can also occur in other tissues including the thymus, lung, and other uncommon sites such as the ovaries, heart, and prostate. Most NETs strongly express somatostatin receptors. Despite the global prevalence of NETs increasing each year, it is considered a rare cancer that is estimated to affect approximately 35/100,000 individuals worldwide. In the United States, around 12,000 patients annually are expected to be diagnosed with neuroendocrine tumors, with an average five-year survival rate of 60% at a metastatic stage.

About Orano Med
Orano Med is a subsidiary of the Orano Group. Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha Therapy (TAT). Leveraging its unique and secured access to 212Pb, the company is developing several 212Pb-based radioligand therapies combined with various targeting agents. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe.

About RadioMedix
RadioMedix, Inc., a clinical-stage biotechnology company and former sponsor of the AlphaMedix trial, is based in Houston and Humble, Texas. The company is focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. RadioMedix is developing radiopharmaceuticals for PET imaging and therapy (alpha- and beta-labeled agents). The company established contract service facilities for academic and industrial partners. including a cGMP and analytical suite for Phase I-II-III clinical trials and commercial launch. To learn more, visit www.radiomedix.com and LinkedIn.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]  
Léo Le Bourhis | +33 6 75 06 43 81 | [email protected]  
Victor Rouault | +33 6 70 93 71 40 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]
Léa Ubaldi | +33 6 30 19 66 46 | [email protected]

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | [email protected]  
Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]
Felix Lauscher | +1 908 612 7239 | [email protected]  
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | +33 7 85 93 30 17 | [email protected]
Tarik Elgoutni | +1 617 710 3587 | [email protected]  
Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]

Orano Med
Regina Jehle | +33 6 74 56 11 31 | [email protected]
Orano Press Office | +33 (0)1 34 96 12 15| [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group with the exception of Orano Med and AlphaMedix™.

Press_Release

About Jamie Ashcroft
Jamie Ashcroft, the News Editor for Proactive UK, has developed an impressive career in financial journalism, focusing on the small-cap sector for over fourteen years. Before joining the Proactive team, he was a stockbroker during the global financial crisis, a role that complemented his educational background - a first-class degree in Business and Economics and qualifications in software design and development.
As one of the early external hires at Proactive in 2009, Jamie contributed... Read more

About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.

Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.

The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.

Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.

Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.

Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.

The Food and Drug Administration approved Gazyva for the treatment of adults receiving standard therapy for a form of lupus that targets the kidneys.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryJPIE invests in a diversified portfolio of bonds, focusing on high-quality MBS.JPIE maintains below-average risk and volatility due to its short duration and high credit quality, making it resilient in various market conditions.It has an above-average 5.8% dividend yield too, with strong, consistent returns in the past and very strong risk-adjusted returns.It is a fantastic, high-quality income ETF, perfect for more risk-averse investors.This idea was discussed in more depth with members of my private investing community, CEF/ETF Income Laboratory. Learn More »Pornyot Palilai/iStock via Getty Images

In keeping with my coverage of high-quality, diversified bond ETFs, I thought to have a second look at the JPMorgan Income ETF (NYSEARCA:JPIE). JPIE offers investors diversified exposure to bonds, with a focus on

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

SummaryFidelity MSCI Consumer Staples Index ETF is rated a buy for its stable, profitable top holdings and defensive sector positioning.FSTA offers low fees (0.08% expense ratio), a solid 2.21% dividend yield, and broad diversification compared to peer consumer staples ETFs.Key holdings—Walmart, Costco, and Procter & Gamble—demonstrate strong revenue, dividend growth, and resilience despite elevated valuations.With declining interest rates and recession risks, FSTA provides a defensive, income-generating option for investors seeking stability and downside protection.Bill Oxford/iStock via Getty Images

Investment Thesis The Fidelity MSCI Consumer Staples Index ETF (NYSEARCA:FSTA) warrants a buy rating due to the profitable, stable revenue of its top holdings. Additionally, the consumer staples sector has historically performed well during times of declining

Analyst’s Disclosure:I/we have a beneficial long position in the shares of WMT, VDC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article is exclusive to Seeking Alpha. No duplication or reproduction of this article is allowed without consent of Seeking Alpha and the author. This article should not be misconstrued as individual financial advice. Always conduct your own due diligence prior to investing.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You